What happens Globalist-Communist science embraces monetary
gain at the expense of the actual public good? YOU GET a Chi-Ná Wuhan COVID-19
virus infecting the world for Communist gain and Globalist power. Consider Part
1 and 2 of the Canada Free Press
articles “Pandemic, Plandemic, or Both?”
JRH 5/23/20
Your generosity is always appreciated - various credit,
check
& debit cards are accepted by my PayPal
account:
Or support by getting in the Coffee from
home business –
OR just buy some
FEEL GOOD coffee, that includes immune boosting products.
**************************
Pandemic, Plandemic, or Both? PT One
By Lee Cary
May 22, 2020
Somewhere along
the way, two-thirds of America’s foundational trilogy of “Life, Liberty, and
the Pursuit of Happiness” abdicated to the first third. So what happened?
The Virus
SARS-CoV-2, also known as the 2019 novel coronavirus, was
shortened to COVID-19. Or, to be politically incorrect, the Wuhan Virus
or China Virus. And, for the very bold, the CCP (Chinese Communist Party)
Virus. SARS means “Severe Acute Respiratory Syndrome”.
SARS-CoV-1 was identified in 2003. The search for a
vaccine has been underway for 17 years. SARS-CoV-1 is thought to have,
perhaps, originated in bats. Perhaps, spread to cats. But surely, first
infected humans in the Guangdong province of southern China in 2002.
SARS-CoV-2 is thought, maybe, to have a similar bat
pedigree, but with a different point of Chinese entry that spread globally.
Whether it was created in a lab, or in nature, is debated.
The Guardians of Public Health
The Centers for Disease Control and Prevention (CDC) “works 24/7 to protect
America from health, safety and security threats, both foreign and in the
U.S.” It opened on July 1, 1946 with 400 employees. In 2018, Forbes reported it had
10,639 “staffers”.
The National Institutes of Health (NIH), founded in the late 1880s, is
“the primary agency of the United States government responsible for biomedical
and public health research”. In 2012, the NIH had 20,262 employees. More
current numbers are unreported. Dr. Tony Fauci, age 79, has directed the NIH
Institute of Allergy and Infectious Diseases since 1984.
The Private Lab: Gilead Sciences
Snapshot:
“Gilead Sciences, Inc., is an American biopharmaceutical company headquartered
in Foster City, California that researches, develops and commercializes drugs.
The company focuses primarily on antiviral drugs used in the treatment of HIV,
hepatitis B, hepatitis C, and influenza, including Harvoni and Sovaldi.”
Gilead News Highlights:
August 2, 2012 – “Gilead
Sciences inks deals with 3 Indian companies including Ranbaxy Laboratories for
low-cost HIV drug” Then, nine months later…
May 13, 2013 – “Generic Drug
Manufacturer Ranbaxy Pleads Guilty and Agrees to Pay $500 Million to Resolve
False Claims Allegations, cGMP Violations and False Statements to the FDA”
“Ranbaxy USA pleaded guilty to
three felony FDCA [Food, Drug, and Cosmetic Act] counts, and four felony counts
of knowingly making material false statements to the FDA [Food and Drug
Administration]. The generic drugs at issue were manufactured at Ranbaxy’s
facilities in Paonta Sahib and Dewas, India…[T]he whistleblower, Dinesh Thakur,
a former Ranbaxy executive, will receive approximately $48.6 million from the
federal share of the settlement amount. The case is U.S. ex rel. Thakur v.
Ranbaxy Laboratories Limited, Case No. JFM-07-962 (D. Md.)”
Also reported, “FDA inspectors
found tablets with a ‘black fibre’ suspected to be human hair and pills with
apparent machinery oil ‘black spots’ at the Mohali plant. Last year,
glass was detected in some pills.”
On behalf of Gilead, Ranbaxy Labs cooked-up gnarly drugs.
August 4, 2014 – Two Gilead
employees bring accusations against their employer in UNITED STATES OF AMERICA,
ex. rel. CAMPIE et al., Plaintiffs, v. GILEAD SCIENCES, INC., et al.,
Defendants.
Jeffery Campie was Gilead’s Senior Director of Commercial
Quality Assurance, and his wife Sherilyn Campie was an Associate Manager of
Quality Control for Gilead.
The two claimed that Gilead had committed “violations of the
False Claims Act (“FCA”), 31 U.S.C. § 3729, et. seq., and analogous
state statutes and city ordinances, claiming that Gilead defrauded the federal,
state, and local governments by selling billions of dollars’ worth of
nonconforming drugs, which were paid for through programs like Medicare,
Medicaid, and the President’s Emergency Plan for AIDS Relief [AKA: PEPFAR]”.
The pair stated that “…Gilead develops, manufactures, and
sells drugs used to treat diseases like HIV/AIDS, hepatitis, and cystic
fibrosis. Gilead manufactured and distributed drug products that failed to meet
applicable specifications because they (1) were contaminated with a host of
adulterants, including, but not limited to, arsenic, cadmium, mercury, lead,
nickel, steel, titanium, chromium, iron, cobalt, aluminum, metal shards, glass,
rubber, polyethylene (plastic), stones or pebbles, cement, paint, wood fibers
and fibrous building materials, organic material, microbes (including bacillus
cereus), paper, Teflon, acetaminophen, other degradants, and blood; (2) were
improperly manufactured using active pharmaceutical ingredients (“API”) [the
part of any drug that produces the intended effects] sourced on the cheap from
unregistered facilities in China and otherwise in violation of federal law and
Good Manufacturing Practices; (3) were subjected to extreme storage and
shipping conditions; and (4) lacked proper testing and analysis…These
nonconforming drugs were paid for by the government through programs like
Medicare, Medicaid and the President’s Emergency Plan for AIDS Relief.”
November 6, 2019 – “United States
Files Patent Infringement Lawsuit Against Gilead Related to Truvada and Descovy
for Pre-exposure Prophylaxis of HIV.”
“In the complaint, HHS [U.S.
Department of Health and Human Services] alleges that Gilead has willfully and
deliberatively induced infringement of the HHS patents. The complaint further
alleges that, as a result of such infringement, Gilead has profited from
research funded by hundreds of millions of taxpayer dollars and reaped billions
from PrEP [Pre-exposure prophylaxis when people at risk for HIV take daily
medicine to prevent HIV] through the sale of Truvada and Descovy.”
In short, the U.S. Government (USG) claims that Gilead
infringed upon USG patents by creating drugs that Gilead sold without rendering
payment due to the USG for use of its patents. Furthermore, Gilead then sold
some of those drugs to the USG. I.e., a kind of double-dipping, or maybe
straight theft.
Gilead Recycles Remdesivir
Gilead Sciences is the biopharmaceutical company that today
markets Remdesivir. It’s the drug selected, by the government doctors in the
white lab coats, to mitigate the symptoms of SARS-CoV-2. It was originally
developed to treat Hepatitis C. When it was tested against the Ebola and
Marburg virus diseases, it failed to work.
When SARS-CoV-2 came along, Remdesivir was taken off the
shelf and used against SARS-CoV-2—not as a cure, but as a stopgap drug to
mitigate symptoms. Hence, the Mayor of Los Angeles awaits a vaccine.
So, was all this the birth of a pandemic, born of a
plandemic, or a child of both?
To be continued in Part 2 of “Pandemic, Plandemic, or
Both?”
++++++++++++++++++++
Pandemic, Plandemic, or Both? (Part 2)
By Lee Cary
May 23, 2020
Review of Part 1 Takeaways
·
When political correctness
is put aside, SARS-CoV-2 is Covid-19’s real name.
·
The combined staff of the
CDC and the NIH is, at last count, about 31,000.
·
The American pharmaceutical
company most engaged in the SARS-CoV-2 episode, Gilead Sciences, has a dodgy
history, and is being sued by the U.S. Government for patent infringement.
·
Gilead’s drug, Remdesivir,
being pushed hard by the federal government’s medical establishment, is a
failed effort left over from the search for a hepatitis C drug.
First U.S. SARS-CoV-2 case used Remdesivir on/about
January 27
Two articles
recount the ordeal of America’s first patient to struggle with the virus.
One is out of Spokane, Washington. The other, dated February
17, 2020, is from the South China Morning Post, out of
Hong Kong, China.
The Post states that the 35-year-old patient flew
into the Seattle-Tacoma International Airport on January 15 after
visiting relatives in Wuhan, China. Few other details are reported in the
Post.
Here’s how a Spokane paper heralded the story: Spokane Spokesman, January 31,
2020, “Washington state coronavirus patient treated with investigational,
unapproved Ebola drug”.
The unnamed male patient was admitted to Providence Regional
Medical Center in Everett, WA on January 20.
Although Remdesivir was not approved for use by the Food and
Drug Administration, it was available if recommended by a physician for
“compassionate use”.
After the drug was administered with patient approval, Dr.
Jay Cook, Chief Medical Officer at Providence, said, “To my knowledge this is
the first reported case in the world where this drug has been used in a human
application against this virus”.
Sometime between January 31 – February 3, the patient was
released from the hospital. No other details are available to the public.
The Spokesman quoted Dr. Scott Lindquist, Washington
State Epidemiologist: “This is a drug that is not available to the general
public. It is released on limited use and really was developed for the Ebola
crisis. We do know that the manufacturer of this product is trying to work
with China to provide this overseas.”
The article states that, “The World Health Organization
declared the outbreak a public health emergency on Thursday (January 30).”
Toward the end of the article, one paragraph signals the
CDC’s threat awareness of the virus at the time:
“While health officials stress that
the likelihood of the novel coronavirus spreading in the U.S. and Washington
is relatively low, anyone who has traveled from Wuhan, China should monitor
their symptoms and contact their health care provider if they experience fever,
cough or shortness of breath. Symptoms can present themselves in as few as two
days or as long as two weeks after exposure, according to the CDC. Risk to
the general public is still low, however.”
Compare the CDC’s threat assessment concerning the “novel
coronavirus” to what Spokane County Health Officer Dr. Bob Lutz said in a May 7
on-line interview with the Spokesman-Review‘s
healthcare reporter who wrote the piece quoted above. The topic was the current
situation and the future with regard to the pandemic in Spokane and the region.
Race to mass produce and distribute Remdesivir was well
underway in China
Lutz: (9:18) ”We were very
ill prepared at the federal level, which, again, has really hampered us at the
state level, and therefore at the local level to really proceed and to really
address the pandemic in a way that we really could have and or should have.”
Reporter: ”…when did you
really start reading about Covid-19 in other parts of the world and start to
get concerned, and I’m curious if you started sounding alarms in our health
district here and started preparing here, when did that thought process begin
with you and started to affect your work?”
Lutz: (10:05) “The first
awareness we had in the United States was soon, you know, late December – early
January, and I think to Department of Health’s credit, as you know, was it in
in the media a week ago, a week and a half ago, they noted that they had
essentially been monitoring Covid-19 for over 100 days. We did not have
formal recognition of monitoring, but with that said, anybody who was in
public health following infectious disease, epidemiology, health officers, we
were well aware of the fact that an epidemic which was certainly in the making
in China was, without doubt, going to move to the United States. And as it
did, we were quickly monitoring it. So I think, that to our credit, we actually
did have an incident command structure, we had that incident command set up in,
I wanna say, late January – early February, and we were meeting…and then,
obviously, when the very first case developed in Washington State, that really
raised everybody’s awareness. So, we saw it coming. We were very much
concerned about it. Were we prepared? Internally, we had done enough
preparation, we had plans in place…(11:35) But overall I would say that it’s
been challenging because the preparation, really not so much locally, and not
so much at the state level, but preparedness was really not to the degree that
it should have been.”
Lutz clearly believes the big federal health agencies
downplayed the threat.
Much of the U.S. media blames President Trump for a
perceived lack of pandemic preparedness. But, the primary responsibility for
preparing to deal with national diseases is assigned to the senior leadership
of the CDC and the NIH. That includes Dr. Anthony Fauci.
Meanwhile, the race to mass produce and distribute
Remdesivir was well underway in China.
Labs in China compete to corner the Remdesivir market
February 17, the Post stated that, “China has begun
enrolling Covid-19 patients into a clinical trial of the antiviral, which was
developed by the pharmaceutical company Gilead.”
February 6: “Wuhan Institute of
Virology Applies for a Patent on Gilead’s Remdesivir”
“The Wuhan Institute of Virology announced on
February 4, 2020 that they applied for a Chinese patent on Gilead’s
Remdesivir for treating the novel coronavirus (2019-nCoV) that originated in
Wuhan in late 2019. The Chinese patent application was filed on January
21, 2020 and the Institute plans to file internationally via
the Patent Cooperation Treaty.”
February 12: “Coronavirus:
China’s BrightGene Manufactures APIs of Gilead’s Remdesivir”
“A publicly traded Chinese drug
developer, BrightGene Bio-Medical Technology Co., said today it has
successfully manufactured the active pharmaceutical ingredients (APIs) of
remdesivir (GS-5734), the Gilead Science antiviral candidate being tested in
China human clinical trials as a treatment for the 2019-nCoV novel
coronavirus.”
“‘[BrightGene] actively responded
to the national call to fight the new coronavirus (2019-nCoV) epidemic, and
recently successfully developed and synthesized the technology and preparations
for the drug synthesis of [remdesivir] technology,’ the company stated today.”
“‘The company successfully imitated
the development and production of [remdesivir] APIs by virtue of its technical
accumulation in the development of high-end APIs and special injections,’
BrightGene added in its statement, issued through the Shanghai Stock Exchange.
‘The company has produced [remdesivir] bulk drugs, and the batch production
of Remdesivir preparations is in progress.’”
“BrightGene acknowledged that its
marketing of remdesivir ‘still needs to be authorized’ by Gilead, adding,
‘There are many uncertainties in this process, such as drug approval.’ BrightGene
did not discuss in its statement what if any efforts the company has undertaken
to pursue authorization from Gilead for the imitation product: ‘If the product
can be approved for marketing, it will be supplied to relevant patients mainly
through donations during the epidemic.’”
“Last week, researchers at China’s Wuhan
Institute of Technology applied for a Chinese patent for the use of Gilead
Sciences antiviral candidate remdesivir as a treatment for coronavirus,
potentially in combination with chloroquine.”
Several China labs rushed to field-test Remdesivir
Meanwhile, as several China labs rushed to field-test
Remdesivir as mitigating the effects of a virus that came out of one of their
facilities – Wuhan Institute of Technology – let’s review Dr. Anthony
Fauci, Director of the National Institute of Allergy and Infectious Diseases,
interview with USA TODAY’s Editorial Board on
Monday, February 17:
“The U.S. Centers for Disease
Control and Prevention will be testing for the coronavirus in people in five
major cities who show up at clinics with flu-like symptoms but who test
negative for the seasonal varieties. If that testing shows the
virus has slipped into the country in places federal officials don’t
know about, ‘we’ve got a problem,’ Dr. Anthony Fauci, director of the National
Institute of Allergy and Infectious Diseases, told USA TODAY’s Editorial Board
Monday.”
“Short of that, Fauci says
skip the masks unless you are contagious, don’t worry about catching anything
from Chinese products and certainly don’t avoid Chinese people or
restaurants…Fauci doesn’t want people to worry about coronavirus, the danger of
which is ‘just minuscule.’ But he does want them to take precautions against
the ‘influenza outbreak, which is having its second wave.”
“‘We have more kids dying of flu
this year at this time than in the last decade or more,’ he said. ‘At the same
time people are worrying about going to a Chinese restaurant. The
threat is (we have) a pretty bad influenza season, particularly dangerous for
our children.’”
SARS-CoV-2 is on the verge of an outbreak in the U.S. and
Fauci is more focused on a possible bad flu season. Dr. Lutz in Eastern
Washington was ahead of him.
On January 26, Fauci told “The Cats
Roundtable” on 970 AM-N.Y. that: “It (Covid-19) isn’t something the American
public needs to worry about or be frightened about, because we have ways of
preparing and screening people coming in [from China].” In short, “We got
this.”
Here’s the status of SARS-CoV-2 at the end of January, and
into early February:
While the leading spokesperson for the federal government’s
medical establishment, Dr. Fauci, is preaching a passive approach to a disease
that the CDC knows has already entered the country in Washington State, Chinese
labs are running full speed to produce Gilead’s Remdesivir in an effort to (1)
service an undisclosed medical need in China and/or (2) corner the market
before the West suffers the full impact of a disease that likely came out of
one of their labs.
Next: The Remdesivir vs. Hydroxychloroquine debate heats
up, amidst censoring from YouTube. And, the initial focus on lab science melds
with political science.
_______________________________
Since November 2007, Lee Cary
has written hundreds of articles for several websites including the American
Thinker, and Breitbart’s Big Journalism and Big Government
(as “Archy Cary”). and the Canada Free Press. Cary’s work was
quoted on national television (Sean Hannity) and on nationally syndicated radio
(Rush Limbaugh, Mark Levin). His articles have posted on the
aggregate sites Drudge Report, Whatfinger, Lucianne, Free Republic, and Real
Clear Politics. He holds a Doctorate in Theology from Garrett Theological
Seminary in Evanston, IL, is a veteran of the US Army Military Intelligence in
Vietnam, and lives in Texas.
Pursuant to Title 17 U.S.C.
107, other copyrighted work is provided for educational purposes, research,
critical comment, or debate without profit or payment. If you wish to use
copyrighted material from this site for your own purposes beyond the 'fair use'
exception, you must obtain permission from the copyright owner. Views are those
of authors and not necessarily those of Canada Free Press. Content is
Copyright 1997-2020 the individual authors. Site Copyright 1997-2020 Canada Free Press.Com
